| 1. Zhao Y, Natarajan V. (2013) Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling.. Biochim Biophys Acta, 1831 (1): (86-92). [PMID:22809994] [10.1021/op500134e] |
| 2. Park GY, Lee YG, Berdyshev E, Nyenhuis S, Du J, Fu P, Gorshkova IA, Li Y, Chung S, Karpurapu M et al.. (2013) Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation.. Am J Respir Crit Care Med, 188 (8): (928-40). [PMID:24050723] [10.1021/op500134e] |
| 3. Bain G, Shannon KE, Huang F, Darlington J, Goulet L, Prodanovich P, Ma GL, Santini AM, Stein AJ, Lonergan D et al.. (2017) Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.. J Pharmacol Exp Ther, 360 (1): (1-13). [PMID:27754931] [10.1021/op500134e] |
| 4. Desroy N, Housseman C, Bock X, Joncour A, Bienvenu N, Cherel L, Labeguere V, Rondet E, Peixoto C, Grassot JM et al.. (2017) Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.. J Med Chem, 60 (9): (3580-3590). [PMID:28414242] [10.1021/op500134e] |
| 5. Orosa B, García S, Conde C. (2015) The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.. Eur J Pharmacol, 765 (13): (228-33). [PMID:26297977] [10.1021/op500134e] |
| 6. Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W et al.. (2019) Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).. BMJ Open Respir Res, 6 (1): (e000422). [PMID:31179008] [10.1021/op500134e] |
| 7. Tang X, Wuest M, Benesch MGK, Dufour J, Zhao Y, Curtis JM, Monjardet A, Heckmann B, Murray D, Wuest F et al.. (2020) Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.. Mol Cancer Ther, 19 (1): (63-74). [PMID:31548293] [10.1021/op500134e] |
| 8. Benesch MGK, Tang X, Brindley DN. (2020) Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.. Cancers (Basel), 12 (2): (1755-70). [PMID:32041123] [10.1021/op500134e] |
| 9. Feng Y, Mischler WJ, Gurung AC, Kavanagh TR, Androsov G, Sadow PM, Herbert ZT, Priolo C. (2020) Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis.. Cancer Res, 80 (13): (2751-2763). [PMID:32393662] [10.1021/op500134e] |
F2208282